Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation

Blood

Volumn 93, Issue 8, 1999, Pages 2738-2747

  Tsukada, Nobuhiro ^b   Kobata, Tetsuji ^b   Aizawa, Yoshifusa ^b   Yagita, Hideo ^b   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CYTOPATHOGENIC EFFECT; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033561434     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.8.2738     Document Type: Article

References (60)

1. Thomas ED: Karnofsky memorial lecture. Marrow transplantation for malignant disease. J Clin Oncol 1:517, 1983
2. Bortin MM, Rimm AA: Increasing utilization of bone marrow transplantation. Transplantation 42:229, 1986
3. Grebe SC, Streilein JW: Graft-versus-host reactions: A review. Adv Immunol 22:119, 1976
4. Gale RP: Graft-versus-host disease. Immunol Rev 88:193, 1985
5. Deeg HJ, Storb R: Graft-versus-host disease: Pathophysiological and clinical aspects. Annu Rev Med 35:11, 1984
6. Lum LG: The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369, 1987
7. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation. Blood 84:3603, 1994
8. Blazar BR, Korngold R, Vallera DA: Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 157:79, 1997
9. Piguet PF, Grau GE, Allet B, Vassalli P: Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the graft-vs.-host disease. J Exp Med 166:1280, 1987
10. Speiser DE, Bachmann MF, Frick TW, Mckall-Faienza K, Griffiths E, Pfeffer K, Mak TW, Ohashi PS: TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 158:5185, 1997
11. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
12. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K: A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood 90:542, 1997
13. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
14. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB: A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157:5387, 1996
15. Baker MB, Riley RL, Podack ER, Levy RB: Graft-versus-host disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perform function. Proc Natl Acad Sci USA 94:1366, 1997
16. Graubert TA, DiPersio JF, Russell JH, Ley TJ: Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100:904, 1997
17. Blazar BR, Taylor PA, Vallera DA: CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64:571, 1997
18. Barnes DWH, Loutit JF: Treatment of murine leukemia with x-rays and homologous bone marrow. Br Med J 2:626, 1956
19. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
20. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068, 1979
21. Gale RP, Champlin RE: How does bone marrow transplantation cure leukemia? Lancet 2:28, 1984
22. Maraninch D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, Leblond V, Michallet M, Dreyfus F, Ifrah N, Bordigoni A: Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukemias. Lancet 2:175, 1987
23. Nash RA, Storb R: Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol 8:674, 1996
24. Datta AR, Barrett AJ, Jiang YZ, Guimarães A, Mavroudis DA, van Rhee F, Gordon AA, Madrigal A: Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions. Bone Marrow Transplant 14:517, 1994
25. Murphy WJ, Longo DL: The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 157:167, 1997
26. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155, 1990
27. Champlin R: Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol 23:1148, 1995
28. van Locham E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host disease and graft-versus-leukemia cytotoxic T-cell activities. Bone Marrow Transplant 10:181, 1992
29. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF: Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen specific cytotoxic T lymphocytes. J Clin Invest 96:877, 1995
30. Faber LM, van Luxemburg-Heijs SAP, Veenhof WFJ, Willemze R, Falkenburg JHF: Generation of CD4+ cytotoxic T lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implication for graft-versus-leukemia reactivity. Blood 86:2821, 1995
31. Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W: Induction of graft-versus-leukemia (GVL) activity in marine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplant 14:711, 1994
32. Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE: Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 157:4811, 1996
33. Seino K, Kayagaki N, Bashuda H, Okumura K, Yagita H: Contribution of Fas ligand to cardiac allograft rejection. Int Immunol 8:1374, 1996
34. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara S, Yagita H, Okumura K: Fas and its ligand in a general mechanisms of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930, 1994
35. Wagner JE, Donnenberg AD, Noga SJ, Cremo CA, Gao IK, Yin HJ, Vogelsang GB, Rowley S, Saral R, Santos GW: Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: Results of a phase I clinical trial. Blood 72:1168, 1988
36. Young JW, Papadopoulos EB, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi MH, Gulati SC, Brochstein JA, Heller G, Black P, Collins NH, Shank B, Kernan NA, O'Reilly RJ: T-cell-depleted allogeneic bone marrow transplantation in adults with nonlymphocytic leukemia in first remission. Blood 79:3380, 1992
37. Filipovich AH, Vallera D, McGlave P, Polich D, Gajl-Peczalska K, Haake R, Lasky L, Blazar B, Ramsay NKC, Kersey J, Weisdorf D: T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation 50: 410, 1990
38. Hale G, Cobbold S, Waldmann H: T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 45:753, 1988
39. Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J: CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 89:3039, 1997
40. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringdén O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
41. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated T-cell depletion. Ann Intern Med 108:806, 1988
42. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, Terasaki P, Billing R, Feig S: Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 105:20, 1986
43. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
44. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 370:650, 1994
45. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, Shinkai Y, Alt FW, Matsuzawa A, Yonehara S, Takayama H: Two distinct pathways of specific killing revealed by perform mutant cytotoxic T lymphocytes. Immunity 1:357, 1994
46. Henkart PA: Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity 1:343, 1994
47. Carter LL, Dutton RW: Relative perforin- and Fas-mediated lysis in T1 and T2 effector populations. J Immunol 155:1028, 1995
48. van den Broek MF, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJM, Zinkernagel RM, Hengartner H: Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184:1781, 1996
49. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31, 1994
50. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G: Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156:13, 1996
51. von Reyher U, Sträter J, Kittstein W, Gschwendt M, Krammer PH, Möller P: Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58:526, 1998
52. Notoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C, Levrero M: Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11:1157, 1995
53. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S: Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791, 1996
54. Dirks W, Schöne S, Uphoff C, Quentmeier H, Pradella S, Drexler HG: Expression and function of CD95 (Fas/Apo-1) in leukaemia-lymphoma tumour lines. Br J Haematol 96:584, 1997
55. Karawajew L, Wuchter C, Ruppert V, Drexler H, Gruss HJ, Dörken B, Ludwig WD: Differential expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 11:1245, 1997
56. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251, 1990
57. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P: The transmambrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793, 1995
58. Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER: Perform, Fas lligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157:1919, 1996
59. Ferrara JLM, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667, 1991
60. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992